Zoetis Inc. (0M3Q.L)
USD 169.5
(-0.56%)
USD 169.5
(-0.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.29 Billion USD | -11.66% |
| 2022 | 10.52 Billion USD | 12.46% |
| 2021 | 9.35 Billion USD | -4.88% |
| 2020 | 9.83 Billion USD | 11.3% |
| 2019 | 8.83 Billion USD | 2.85% |
| 2018 | 8.59 Billion USD | 26.35% |
| 2017 | 6.8 Billion USD | 10.57% |
| 2016 | 6.15 Billion USD | -9.85% |
| 2015 | 6.82 Billion USD | 29.45% |
| 2014 | 5.27 Billion USD | -5.83% |
| 2013 | 5.59 Billion USD | 151.96% |
| 2012 | 2.22 Billion USD | 12.46% |
| 2011 | 1.97 Billion USD | 1.8% |
| 2010 | 1.94 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 9.12 Billion USD | -0.89% |
| 2024 Q2 | 9.2 Billion USD | -0.98% |
| 2024 Q1 | 9.29 Billion USD | 0.01% |
| 2023 Q4 | 9.29 Billion USD | 2.91% |
| 2023 FY | 9.29 Billion USD | -11.66% |
| 2023 Q2 | 9.12 Billion USD | -1.46% |
| 2023 Q3 | 9.03 Billion USD | -1.05% |
| 2023 Q1 | 9.26 Billion USD | -11.97% |
| 2022 Q4 | 10.52 Billion USD | 16.76% |
| 2022 FY | 10.52 Billion USD | 12.46% |
| 2022 Q2 | 9.19 Billion USD | -0.13% |
| 2022 Q1 | 9.2 Billion USD | -1.65% |
| 2022 Q3 | 9.01 Billion USD | -1.94% |
| 2021 Q2 | 9.71 Billion USD | 0.13% |
| 2021 Q3 | 9.02 Billion USD | -7.13% |
| 2021 FY | 9.35 Billion USD | -4.88% |
| 2021 Q1 | 9.7 Billion USD | -1.34% |
| 2021 Q4 | 9.35 Billion USD | 3.68% |
| 2020 Q4 | 9.83 Billion USD | -2.79% |
| 2020 FY | 9.83 Billion USD | 11.3% |
| 2020 Q1 | 8.77 Billion USD | -0.7% |
| 2020 Q2 | 10.08 Billion USD | 14.89% |
| 2020 Q3 | 10.11 Billion USD | 0.36% |
| 2019 Q4 | 8.83 Billion USD | 2.83% |
| 2019 Q1 | 8.56 Billion USD | -0.3% |
| 2019 Q2 | 8.57 Billion USD | 0.11% |
| 2019 Q3 | 8.59 Billion USD | 0.22% |
| 2019 FY | 8.83 Billion USD | 2.85% |
| 2018 Q4 | 8.59 Billion USD | 3.01% |
| 2018 FY | 8.59 Billion USD | 26.35% |
| 2018 Q3 | 8.34 Billion USD | 25.98% |
| 2018 Q2 | 6.62 Billion USD | -1.4% |
| 2018 Q1 | 6.71 Billion USD | -1.25% |
| 2017 Q3 | 7.26 Billion USD | 20.03% |
| 2017 FY | 6.8 Billion USD | 10.57% |
| 2017 Q2 | 6.05 Billion USD | 0.7% |
| 2017 Q1 | 6.01 Billion USD | -2.21% |
| 2017 Q4 | 6.8 Billion USD | -6.45% |
| 2016 FY | 6.15 Billion USD | -9.85% |
| 2016 Q1 | 6.26 Billion USD | -8.15% |
| 2016 Q3 | 6.11 Billion USD | -0.49% |
| 2016 Q2 | 6.14 Billion USD | -1.9% |
| 2016 Q4 | 6.15 Billion USD | 0.54% |
| 2015 FY | 6.82 Billion USD | 29.45% |
| 2015 Q2 | 5.39 Billion USD | 5.29% |
| 2015 Q4 | 6.82 Billion USD | 25.59% |
| 2015 Q3 | 5.43 Billion USD | 0.67% |
| 2015 Q1 | 5.12 Billion USD | -2.75% |
| 2014 Q1 | 5.3 Billion USD | -5.22% |
| 2014 Q2 | 5.23 Billion USD | -1.23% |
| 2014 Q3 | 5.13 Billion USD | -1.93% |
| 2014 Q4 | 5.27 Billion USD | 2.57% |
| 2014 FY | 5.27 Billion USD | -5.83% |
| 2013 FY | 5.59 Billion USD | 151.96% |
| 2013 Q1 | 5.41 Billion USD | 143.94% |
| 2013 Q2 | 5.43 Billion USD | 0.37% |
| 2013 Q3 | 5.39 Billion USD | -0.83% |
| 2013 Q4 | 5.59 Billion USD | 3.76% |
| 2012 Q4 | 2.22 Billion USD | 23.73% |
| 2012 Q2 | 1.86 Billion USD | -4.45% |
| 2012 Q3 | 1.79 Billion USD | -3.96% |
| 2012 FY | 2.22 Billion USD | 12.46% |
| 2012 Q1 | 1.95 Billion USD | -0.96% |
| 2011 FY | 1.97 Billion USD | 1.8% |
| 2011 Q4 | 1.97 Billion USD | 0.0% |
| 2010 FY | 1.94 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -6094.354% |
| Dynavax Technologies Corporation | 375.02 Million USD | -2378.508% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -1806.819% |
| Perrigo Company plc | 6.04 Billion USD | -53.86% |
| Illumina, Inc. | 4.36 Billion USD | -112.895% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 82.085% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -4648.695% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 86.501% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 54.811% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -3524.078% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | -30.785% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -24824.917% |
| Waters Corporation | 3.47 Billion USD | -167.366% |
| Biogen Inc. | 12.04 Billion USD | 22.834% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -11175.824% |
| Evolus, Inc. | 209.68 Million USD | -4332.797% |
| Adicet Bio, Inc. | 37.12 Million USD | -24940.409% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -13418.23% |
| bluebird bio, Inc. | 424.62 Million USD | -2088.995% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -1306.65% |
| FibroGen, Inc. | 585.72 Million USD | -1486.914% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -89.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -26323.429% |
| Homology Medicines, Inc. | 118.53 Million USD | -7741.698% |
| Geron Corporation | 146.12 Million USD | -6260.905% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -129.476% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -1404.761% |
| Myriad Genetics, Inc. | 312.9 Million USD | -2870.598% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -46210.597% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -3606.022% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -18801.497% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -165.155% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -391.785% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -80.492% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -19086.707% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -257.035% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -3411.058% |
| Verastem, Inc. | 71.18 Million USD | -12957.526% |
| Nektar Therapeutics | 267.04 Million USD | -3380.674% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -2239.783% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -23006.946% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -286.448% |
| OPKO Health, Inc. | 622.47 Million USD | -1393.223% |
| Exelixis, Inc. | 678.44 Million USD | -1270.045% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -811.811% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -7995.844% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -74058.289% |
| uniQure N.V. | 624.01 Million USD | -1389.538% |
| Imunon, Inc. | 8.53 Million USD | -108862.892% |
| Blueprint Medicines Corporation | 918.64 Million USD | -911.821% |
| Insmed Incorporated | 1.66 Billion USD | -459.347% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -463.517% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -7271.192% |
| TG Therapeutics, Inc. | 169.08 Million USD | -5397.235% |
| Incyte Corporation | 1.59 Billion USD | -483.758% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -683.991% |